Why Barclays PLC Stock Is Rising as UK Bank Shares Rebound Before Fed, BoE

Why Barclays PLC Stock Is Rising as UK Bank Shares Rebound Before Fed, BoE

March 18, 2026

LONDON, March 18, 2026, 13:48 GMT

Barclays PLC gained roughly 1.6% in London on Wednesday, pushing shares to near 400 pence and ranking the bank as one of the FTSE 100’s top performers. This came on the heels of a 1.44% climb Tuesday, with Barclays outpacing the wider market both days. Hargreaves Lansdown

The gain is significant with investors recalibrating expectations for UK and U.S. rates. Global markets held firm as oil prices slipped, traders keeping an eye on the Fed. Over at J.P. Morgan, analysts pushed out their forecast for the Bank of England’s next cut, now eyeing the first quarter of 2027. Reuters

Bank stocks have felt the impact of that shift. On Wednesday, UK financials climbed 1.9%, following a 1.3% bump for the sector on Tuesday that had already given the FTSE 100 a push higher. Reuters

Barclays appears better insulated from the direct effects of the Middle East turmoil than certain European peers. According to J.P. Morgan, HSBC and Standard Chartered carry the highest exposure to the region among big European lenders. Barclays, along with a handful of others, keeps its exposure below 1% by both revenue and profit metrics. Reuters

Still, the trade isn’t without risk. S&P Global reported this week that UK consumer sentiment dropped to its lowest point since January 2025. Economist Maryam Baluch described the move as among the “first tangible signs” of the conflict’s impact on the domestic economy. Reuters

Capital returns are also giving Barclays shares some lift. On Feb. 10, the bank reported a 12% jump in 2025 pretax profit to 9.1 billion pounds. It raised its return-on-tangible-equity target to above 14% for 2028 and outlined plans to return over 15 billion pounds to shareholders between 2026 and 2028. Reuters

That figure factors in a 1 billion pound buyback. According to Barclays’ investor relations site, the buyback program unveiled on Feb. 10 was scheduled to kick off in the first quarter. Then, just two days ago, a company filing disclosed that the bank repurchased 2,992,834 ordinary shares between March 12 and March 13. Barclays

Energy prices rewriting the policy script have economists pulling back. Dani Stoilova over at BNP Paribas Markets 360 called the route to a fresh Bank of England cut “narrower and narrower by the day.” Paul Dales from Capital Economics figures officials will “play for time.” Reuters

Flows could also be a factor here. Goldman Sachs reported that hedge funds “aggressively shorted” financial stocks during the week ending March 13. Banks, noted Erlen Capital Management’s Bruno Schneller, have turned into “liquid proxies” for those looking to hedge wider credit risk. Reuters

Barclays’ American depositary receipts traded in New York rose 1.6% to $21.14 as of 13:19 UTC, mirroring gains seen in London.

Marcin Frąckiewicz

Marcin Frąckiewicz is the CEO of TS2 Space and a longtime technology entrepreneur focused on telecommunications, satellite communications and digital innovation. A graduate of the Warsaw School of Economics (SGH), he writes about space technology, artificial intelligence and publicly traded technology companies. His analysis covers major market trends, emerging technologies and the businesses shaping the future of the global economy.

Stock Market Today

  • Pro Medicus Stock Soars Post Echo IQ Deal, Valued at A$1 Billion
    June 26, 2026, 4:15 PM EDT. Pro Medicus (ASX:PME) closed at A$188.88 on June 26, rising 1.9% on the day and 9.3% over the week, fueled by a deal with Echo IQ (ASX:EIQ) valued at A$20 million but generating an effective market cap increase of approximately A$1.03 billion. This deal involves a proposed U.S. reseller agreement for EchoSolv AI tools, with final legal documents expected within 20 business days. Echo IQ will receive A$10 million in secured convertible notes initially, paying 12.5% interest, secured by AI cardiovascular algorithms. The surge reflects investor confidence in Pro Medicus leveraging Visage 7 Cardiology software to expand into AI distribution. Despite being dropped from the S&P/ASX 50 index, the stock gains suggest strong sector interest amid broader market stagnation.